Saudi Arabia’s SAJA Pharma bought a 51% stake in Egyptian pharma company Biopharm, according to Al Borsa. The acquisition, whose was not revealed, was followed by an additional EGP 132.6 mn by SAJA into the company. The move comes as part of a strategy to increase their presence in Egypt. Baker and Mckenzie was the legal advisor on the transaction.
More from Enterprise
The National Bank of Egypt and Banque Misr just hiked rates on CDs — moves that could see the EGP gain against the USD
NBE and BM both hiked rates on CDs by 125…
Miga guarantee unlocks USD 313 mn for National Bank of Egypt trade finance
Plus: Incolease taps securitization market with debut EGP 2 bn…
Swvl is not dropping off of Nasdaq just yet, as company turns to the black in 2025
The company turned a profit last year, allowing it to…
Kiwe gets Central Bank green light to launch nationwide
The startup is backed by our friends at EFG Hermes,…